title: Does levodopa affect metaiodobenzylguanidine myocardial accumulation in Parkinson's disease?
authors.forename: Masahiko
authors.initials: M
authors.lastname: Kishi
authors.forename: Ryuji
authors.initials: R
authors.lastname: Sakakibara
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Terada
authors.forename: Emina
authors.initials: E
authors.lastname: Ogawa
authors.forename: Terada
authors.initials: T
authors.lastname: Tateno
mesh_terms: D019797:3-Iodobenzylguanidine / Q000378:metabolism*; D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007980:Levodopa / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism*; D010300:Parkinson Disease / Q000188:drug therapy / Q000473:pathology; D011877:Radionuclide Imaging / Q000379:methods
chemical_list: D000978:Antiparkinson Agents; D019797:3-Iodobenzylguanidine; D007980:Levodopa